Prognostic value of pretreatment tumor-to-blood Standardized Uptake Ratio (SUR) in rectal cancer

No Thumbnail Available

Date

2020-06

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

Objectives: The prognostic value of SUV on pretreatment F-18 FDG PET/CT imaging in patients with rectal cancer is a matter of debate. SUR is of prognostic value for survival in different cancers. In this study, we aimed to examine the potential prognostic value of SUR and other parameters in pretreatment F-18 FDG PET/CT for non-metastatic rectal cancer. Methods: One hundred four non-metastatic rectal cancer patients who underwent pretreatment PET/CT between March 2012 and January 2018 were included in the study. Firstly, SUVmax, SUVmean, MTV, and TLG were calculated semi-automatically at the workstation. SUR was calculated as the ratio of tumor SUVmax to thoracic aorta blood SUVmean. Univariate Cox regression and Kaplan–Meier analysis were used to evaluate overall survival (OS), progression free survival (PFS), and local recurrence (LR). Then, multivariate Cox regression analysis, which included the parameters that were significant in the univariate analysis, was performed. Results: Multivariate Cox regression analysis revealed that SUR was a prognostic factor for PFS. Age and T stage were prognostic factors for both OS and PFS. MTV was found to be independent risk factors for OS. Conclusions: In our study, SUR was the only F-18 FDG PET/CT parameter found to be significant for PFS. The development of new parameters can increase the prognostic value of F-18 FDG PET/CT.

Description

Keywords

Fluorodeoxyglucose f18, Positron-emission tomography, Prognosis, Rectal cancer, Sur, Survival, Positron-emission-tomography, Brain transfer constants, Cell lung-canger, Colorectal-cancer, F-18-fdg pet, Fdg-pet/ct, Volumetric parameters, Graphical evaluation, Renal-failure, Survival

Citation

Belge, G. vd. (2020). Prognostic value of pretreatment tumor-to-blood Standardized Uptake Ratio (SUR) in rectal cancer". Annals of nuclear medicine, 34(6), 432-440